Sep
08
2020
08
2020
SporeGen® Announces Collaboration with Destiny Pharma Supported by an Innovate UK grant award to Co-develop Novel, Preventative Treatment for COVID-19
· SPOR-COVTM prophylactic approach targets the innate immune system with potential to develop COVID-19 protection within a few days of treatment
· Innovate UK grant of £800,000 to support SPOR-COV programme over the next 18 months
Read More